The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy

Apr 28, 2019The Journal of pharmacology and experimental therapeutics

The drug KBP-088 reduces weight and improves insulin response better than long-term amylin treatment

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

KBP-088 (5g/kg) reduced body weight by 15% in high-fat diet rats, outperforming all doses of amylin.

Acute dosing with KBP-088 resulted in a greater reduction in food intake compared to amylin at doses of 100, 300, and 1000g/kg.
Chronic administration of KBP-088 was more effective than amylin in promoting body weight loss and reducing overall body fat.
KBP-088 also improved oral glucose tolerance with an 80% reduction in insulin levels, surpassing the reductions seen with amylin.
Amylin's effectiveness in chronic treatment was less than that of KBP-088, regardless of the dose administered.
The enhanced effects of KBP-088 suggest that dual activation of amylin and calcitonin receptors may play a significant role.

AI simplified

KBP-088 (KeyBiosciencePeptide 088) is a potent dual amylin and calcitonin receptor agonist (DACRA). DACRAs are known to elicit potent activity in terms of typical amylin-induced responses, such as reducing food intake and body weight. However, to what extent amylin infusion can mimic the effects of the dual agonist KBP-088 is unknown. We studied the effect of acute dosing with KBP-088 (5g/kg) and rat amylin (100, 300, and 1000g/kg) and subsequently compared the chronic effect of KBP-088 (5g/kg per day) to increasing doses of rat amylin (100, 300, and 1000g/kg per day) delivered by continuous subcutaneous infusion, in high-fat diet (HFD) fed Long-Evans rats. Furthermore, acute amylin sensitivity was investigated. Single dose KBP-088 (5g/kg) potently reduced acute food intake for a prolonged period compared with amylin (100, 300, and 1000g/kg), confirming the difference in potency. Independent of dose, chronic amylin administration (100, 300, and 1000g/kg per day) was less effective than KBP-088 (5g/kg per day) in inducing body weight loss (15% with KBP-088, and 5%, 9%, and 8% with amylin, vehicle corrected) and reducing overall adiposity in HFD rats. Moreover, KBP-088 improved oral glucose tolerance with significantly reduced insulin levels (80% reduction) that were better than all doses of amylin (68%, 53%, and 7% reduction). Acute amylin sensitivity was independent of the chronic treatment. Dual activation of amylin and calcitonin receptors by KBP-088 is superior to amylin in reducing body weight and improving glucose tolerance, indicating a role for the calcitonin receptor. µ µ µ µ µ µ µ µ

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief